R2 is now Rivian’s top seller, and Q4 looks bigger. Here is why that matters more than...
Skyrizi and Rinvoq now dwarf Humira. Watch Q3 for the cleanest read yet.
TMUS's 34% EPS jump and raised guidance point beyond wireless.
Q3 results land this morning, and the margin line without last quarter's tariff refunds is what investors...
Three consecutive beat-and-fade quarters raise a real question: has the market stopped paying for 13% revenue growth...
A hawkish hold with possible dissents from Hammack, Kashkari and Logan sets up December as the real...
A court loss for Novo Nordisk clears Lilly's marketing runway into open enrollment — right as the...
With $6.1B due by end-2028 and a $3B Sandals deal, the question is whether guidance holds.
With $635.6 million leaving spot funds on Oct. 22 and the Fed deciding Wednesday, COIN and MSTR...
Pending home sales just hit a Redfin record low, Bessent pushed Fannie/Freddie changes out, and D.R. Horton...